Related Experiment Video

Updated: Jun 26, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

Recent patents and patent applications relating to mTOR pathway

Xiangyu Liu1, Zhenyu Yue

  • 1Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA.

Recent Patents on DNA & Gene Sequences
|January 20, 2009
PubMed

Insights

Recent patents focus on the mammalian target of rapamycin (mTOR) pathway, a key regulator of cell growth. These innovations target mTOR-associated cancers and metabolic diseases, including obesity and diabetes.

Area of Science:

  • Biochemistry and Molecular Biology
  • Oncology
  • Metabolic Diseases

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for regulating cell growth, proliferation, and metabolism.
  • Dysregulation of the mTOR pathway is implicated in various human diseases, including cancers and metabolic disorders like obesity and diabetes.
  • Rapamycin and its analogs are established mTOR inhibitors with therapeutic potential, particularly in oncology.

Purpose of the Study:

  • To review recent patents and patent applications concerning the mTOR pathway.
  • To discuss therapeutic strategies targeting mTOR for metabolic diseases.
  • To analyze patent landscape for mTOR-driven cancer treatments.

Main Methods:

  • Comprehensive literature search of patent databases.
  • Analysis of patent filings related to mTOR inhibitors and their therapeutic applications.
  • Review of patents focused on metabolic diseases and cancer treatment.

Main Results:

  • Significant patent activity exists for mTOR inhibitors and their analogs.
  • Emerging patents address the use of mTOR modulation in treating obesity, diabetes, and related metabolic conditions.
  • Numerous patents are dedicated to novel mTOR-targeting anticancer therapies.

Conclusions:

  • The patent landscape indicates intense research and development in targeting the mTOR pathway for therapeutic interventions.
  • Future therapeutic strategies will likely leverage mTOR inhibition for both oncological and metabolic diseases.
  • Patent analysis provides insights into the direction of innovation for mTOR-associated disease treatments.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...